Navigation Links
Gut research yields new anti-cancer approach

s disease and ulcerative colitis, bowel diseases that cause pain and diarrhea. Specifically, they were comparing the effect on inflammation of encouraging the action of the PPARgamma protein (with activator compounds) against discouraging it (with inhibitors). The team conducted these experiments using colorectal cancer cells as study models because they arise from normal gut cells and share some of their qualities (e.g. normal inflammatory signals). Unlike normal gut cells, however, cancer cells do not die when removed from the gut wall. Living on in the absence of normal survival signals makes cancer cells dangerous in the body, but useful as cell lines for study.

While comparing PPARgamma activators and inhibitors, Schaefer noted with frustration that her cancer cells were dying before she could complete her experiments. Retracing her steps, she found that she had used too much inhibitor. The team, led by Lawrence J. Saubermann, M.D., associate professor of Medicine at the Medical Center, realized they had come across a potentially new therapeutic effect, and launched experiments to confirm it.

Study Details

In the newly published study, researchers observed the effects of three compounds known from the literature to inhibit PPARgamma, T0070907, GW9662 and BADGE, on the ability of colorectal tumor cells to survive. High doses (10-100 ìM) of all three interfered with colorectal cancer cell growth, reduced the cells' ability to spread through the bloodstream to cause new tumors elsewhere (metastasize) and caused cells to self-destruct, generally within 24 hours. Further experiments showed that high-dose PPARgamma inhibition destroyed cancer cell microtubules, protein structures that form part of the skeleton of cells.

Beyond providing structural support and shape to cells, microtubules expand and shrink to generate the force needed for cells to divide, a basic process in tumor growth. Microtubules are made of two rel
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4

Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers

Post Your Comments:
(Date:11/26/2009)... (methicillin-resistant Staphylococcus Aureus ) a...lation as low-temperature plasma prototype devices...d unfailing bactericidal cocktails. , Two protot... disinfection of healthy skin (e.g. hands and feet...n pose a lethal threat; and another to shoot bacte...
(Date:11/25/2009)...ns, Ga. Bacteria don,t have easy lives. In additi...gs, they have natural enemies called bacteriophage...ery two days. , Still, bacteria and another cla...red in extreme environments such as deep-sea volca...cause they have a built-in defense system that hel...
(Date:11/25/2009)...SON, WI, NOVEMBER 25, 2009 Soil is the linchpin o...d hydrosphere meet. Despite that, many students se... nothing more. Soil science educators are challeng...c recognize the critical importance of soil in the... science and earth science teachers at University ...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3It's not just dirt! 2Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 1Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 2Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 3Two Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride 48149 4One of Womens Best Kept Secrets is Now Available in the Mens Department 48145 1One of Womens Best Kept Secrets is Now Available in the Mens Department 48145 2
... advance in the study of the complex receptors and...rs at the University of California, San Diego (UCS...ling pathways that impact activation of a receptor...o the thrombosis that occurs in heart attacks and ...the signaling pathway that regulates activation of...
...ave been exposed to biological or chemical weapons...IT researchers who are helping to develop a tiny d.... , By tweaking the design of a tiny pump, researc...anotechnologies have taken a major step towards ma...ortable, so the tiny device can perform hundreds o...
...th,s Vaccine 1 highlights the huge gap between cur...commendations endorsed by the European Union. Curr...ations are receiving seasonal influenza vaccine in...lisations and mortality. , For the first time, r...able European public health officials to visualise...
Other Biology News:UCSD researchers create roadmap to integrin activation 2UCSD researchers create roadmap to integrin activation 3MIT designs portable 'lab on a chip' 2MIT designs portable 'lab on a chip' 3First-time analysis reveals millions of Europeans left at risk from influenza 2First-time analysis reveals millions of Europeans left at risk from influenza 3
(Date:11/30/2009)...Md., Nov. 30 Novavax, In...ed enrollment in the Phase II clinical study of it...ded strains) VLP vaccine candidate in healthy adul...randomized, double-blind, active-controlled study ...nicity of two different doses (15 mcg and 60 mcg) ...
(Date:11/30/2009)...NGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTec...nology, and medical-device research and,developmen... the United States,announced that it had been sel...9 list for the fifth consecutive year. The list re...,s technology, media, and telecommunications,indus...
(Date:11/27/2009)..., N.C., Nov. 27 Cromoz Inc., locat...soluble carbon nanotube-based cancer drug delivery...bon nanotubes, which have functional groups on the...gs, was developed in partnership with the Indian I...notubes serves as a drug delivery vehicle with the...
(Date:11/25/2009)..., Nov. 25 Biotech firm Replikins L...ta from the 1918 pandemic through the prediction, ...c, today issued its latest biochemical analysis of...of the H1N1 ("Swine Flu") virus has dropped from i...nt outbreak in the spring of 2009 to resting non-e...
Breaking Biology Technology:NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5
...tiles,Transnational Corp. today announced the expa...ratories and Clinical Development Services (CDS) u...ess in China., The new consolidated Quintiles Chi...space, is located at Sun Dong Ann Plaza in Beijing...e Peking Union Medical College,Hospital (PUMCH). T...
...drug,and diagnostic discovery company, announced t...gic partnership with bioMerieux in the field of,ca..., ExonHit will gain,commercial rights on the diagn...ioMerieux will have a greater flexibility to initi...field., The partnership, initiated in October 200...
..., the global,leader in cold chain visibility solut...ility - A Discussion and Review of Industry,Implem...estment" at IQPC,(International Quality & Producti...ium. Sensitech is a wholly owned subsidiary of Car...SE: UTX )., (Logo: http://www.newscom.com/cgi-b...
Other Biology Technology:Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility 2ExonHit and bioMerieux Amend Their Strategic Partnership 2ExonHit and bioMerieux Amend Their Strategic Partnership 3Sensitech to Sponsor Panel Session at IQPC Cool Chain Europe 2008 2Sensitech to Sponsor Panel Session at IQPC Cool Chain Europe 2008 3
Easy Pierce 20 m from ABgene
NucleoSpin Extract II from MACHEREY-NAGEL
Anti-Transglutaminase II Monoclonal Antibody, Unconjugated, Clone CUB7402 from Diagnostic BioSystems
... Tecans fully automated solution for cell culture ...tion for cell-line maintenance, expansion, harvest...lt upon standard, industry proven components: A ...both rapid bulk media dispensing and precise small...
Biology Products: